These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 30134184)
1. MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells. Respondek M; Beberok A; Rok J; Rzepka Z; Wrześniok D; Buszman E Toxicol In Vitro; 2018 Dec; 53():126-135. PubMed ID: 30134184 [TBL] [Abstract][Full Text] [Related]
2. MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage. Respondek M; Beberok A; Rzepka Z; Rok J; Wrześniok D Fundam Clin Pharmacol; 2020 Feb; 34(1):20-31. PubMed ID: 31410885 [TBL] [Abstract][Full Text] [Related]
3. Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes. Respondek M; Beberok A; Rzepka Z; Rok J; Wrześniok D Pathol Oncol Res; 2020 Jul; 26(3):1465-1474. PubMed ID: 31432325 [TBL] [Abstract][Full Text] [Related]
4. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells. Atif F; Patel NR; Yousuf S; Stein DG PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872 [TBL] [Abstract][Full Text] [Related]
5. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide. Séry Q; Rabé M; Oliver L; Vallette FM; Gratas C Biochem Biophys Res Commun; 2017 Dec; 493(4):1377-1383. PubMed ID: 28970067 [TBL] [Abstract][Full Text] [Related]
6. An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective. Pawlowska E; Szczepanska J; Szatkowska M; Blasiak J Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562589 [TBL] [Abstract][Full Text] [Related]
7. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
9. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. Gratas C; Séry Q; Rabé M; Oliver L; Vallette FM Oncotarget; 2014 May; 5(9):2428-35. PubMed ID: 24811082 [TBL] [Abstract][Full Text] [Related]
10. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Bektas M; Johnson SP; Poe WE; Bigner DD; Friedman HS Cancer Chemother Pharmacol; 2009 Oct; 64(5):1053-8. PubMed ID: 19597728 [TBL] [Abstract][Full Text] [Related]
11. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Tian T; Mingyi M; Qiu X; Qiu Y Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996 [TBL] [Abstract][Full Text] [Related]
13. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway. Xu P; Zhang G; Hou S; Sha LG Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215 [TBL] [Abstract][Full Text] [Related]
14. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells. Gjika E; Pal-Ghosh S; Kirschner ME; Lin L; Sherman JH; Stepp MA; Keidar M Sci Rep; 2020 Oct; 10(1):16495. PubMed ID: 33020527 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
17. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Montaldi AP; Godoy PR; Sakamoto-Hojo ET Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369 [TBL] [Abstract][Full Text] [Related]
18. Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells. Alexiou GA; Gerogianni P; Vartholomatos E; Kyritsis AP Cancer Invest; 2016 Nov; 34(10):489-495. PubMed ID: 27768402 [TBL] [Abstract][Full Text] [Related]
19. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399 [TBL] [Abstract][Full Text] [Related]
20. Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Hanif F; Perveen K; Malhi SM; Jawed H; Simjee SU Toxicol In Vitro; 2018 Oct; 52():306-313. PubMed ID: 30003979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]